HKMPF News and Press, Hikma Pharmaceuticals Plc From 04/20/22

Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) said it received preliminary approval from the U.S. Federal Trade Commission for its its acquisition of Custopharm from Water Street Healthcare Partners. The company said the parties have now obtained all regulatory approvals require...

Hikma Pharmaceuticals PLC (HKMPF) Q4 2021 Earnings Conference Call February 24, 2022 4:30 AM ET Company Participants Sigurdur Olafsson - Chief Executive Officer Khalid Nabilsi - Chief Financial Officer Conference Call Participants Emily Field - Barclays Bank Peter Verdult - Citigroup Thibault...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2021 Q4 earnings call. For further details see: Hikma Pharmaceuticals PLC 2021 Q4 - Results - Earnings Call Presentation

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Despite the first months of the quarter favoring growth, ...

AMRN shares are up almost 30% last month, likely due in part to AMRN's success in keeping generics to 11% market share and the imminent European launch. AMRN share price is still near its lows since it reported its REDUCE-IT data in 2018. As the Nevada ANDA litigation ends as an A...

Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine. The company has completed a Phase II trial of the vaccine but hasn't released any data from the trial. BeyondSpring, a New York City-China ...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2021 Q2 earnings call. For further details see: Hikma Pharmaceuticals PLC 2021 Q2 - Results - Earnings Call Presentation

Hikma Pharmaceuticals PLC (HKMPF) Q2 2021 Earnings Conference Call August 6, 2021 4:30 AM ET Company Participants Layan Kalisse – Investor Relations Analyst Sigurdur Olafsson – Chief Executive Officer Khalid Nabilsi – Chief Financial Officer Conference Call Participants P...

The FDA has approved Hikma Pharmaceuticals' (HKMPF) Kloxxado (naloxone hydrochloride) nasal spray 8mg, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Kloxxado contains ...

Hikma Pharmaceuticals ([[HKMPF]] -2.1%) has signed an exclusive license and distribution agreement with AFT Pharmaceuticals for the commercialisation of Combogesic IV, an intravenous, opioid free post-operative pain relief medicine.The licensing agreement provides Hikma with exclusi...